期刊文献+

γ射线辐照后NK92细胞对HOS骨肉瘤细胞杀伤作用的体外研究 被引量:1

Ex-vivo study of the cytolytic effect of γ-ray-irradiated NK92 cells against HOS osteosarcoma cells
原文传递
导出
摘要 [目的]研究NK92细胞经γ射线辐照后的增殖活性及对HOS骨肉瘤细胞的体外杀伤效应变化;观察rhIL-12对γ射线辐照后NK92细胞的胞毒杀伤效力的影响。[方法]应用^60Coγ射线发生器对NK92进行照射处理,照射剂量分别为0,3,10Gy,靶细胞为K562细胞及HOS细胞,其中K562细胞为阳性对照。MTT法检测NK92细胞经射线受照后的增殖能力及不同处理条件下NK92细胞对靶细胞的杀伤活性。将2ng/ml rhIL-12加入预照射处理后的NK92培养基中孵育过夜,检测rhIL-12对1射线辐照后NK92细胞的胞毒杀伤效力的影响,流式细胞术检测细胞表面Fas表达的变化。[结果]随着效靶比梯度的变化,NK92对HOS的杀伤率在4.3%-48.0%之间。与未照射组相比,经射线处理后的NK92细胞对靶细胞的杀伤率差异无统计学意义(P〉0.05)。2ng/ml rhIL-12能明显提高NK92细胞及γ射线辐照后的NK92细胞的体外杀伤作用(P〈0.05)。[结论]γ射线辐照后的NK92细胞对HOS细胞具有良好的杀伤活性,同时其自身增殖活性明显降低,可作为骨肉瘤过继免疫治疗的理想效应细胞。此外,rhIL-12能明显提高NK92细胞对靶细胞的杀伤活性,起到良好正向调节作用。 [ Objective] To study the cytotoxic activity of T- ray-irradiated NK92 cells against HOS osteosarcoma cells and to investigate the cytolytic effect of rhlL - 12 - stimulated effector cells against the target cells. [ Methods] NK92 cells were exposed to different doses of radiation, orstimulated by 2ng/mLof rhlL - 12 for approximately 24h. We measured the cytotoxic activity of NK92 cells against targets by using the MTT colorimetric method and the quantity of Fas present on the surface of the osteosarcoma cells by using flow cytometry. [ Results ] The cytotoxic activity of NK92 cells against HOS was approximately 4. 3% -48%. In contrast to the control group, the cytotoxic activity of the NK92 cells irradiated against the target cells was only minimally greater, but that of the rhlL - 12 - stimulated NK92 cells was significantly higher. [ Conclusion] As T - ray - irradiated NK92 cells have excellent eytotoxic effecton HOS cells and reduce their proliferation activity significantly, they could be ideal for adoptive immunotherapy for osteosarcoma. As rhIL - 12 increases the cytotoxic activity of NK92 cells significantly, it has a good upregulating effect.
出处 《中国矫形外科杂志》 CAS CSCD 北大核心 2013年第21期2212-2217,共6页 Orthopedic Journal of China
基金 湖北省生物靶向治疗研究重点实验室开放课题资助项目(编号:2007B08)
关键词 NK细胞系 过继免疫治疗 骨肉瘤 IL-12 natural killer cell lines, adoptive immunotherapy, osteosarcoma, interleukin - 12 ( IL - 12 )
  • 相关文献

参考文献16

  • 1仇志强,廖琦.骨肉瘤治疗的研究进展[J].中国修复重建外科杂志,2010,24(12):1469-1475. 被引量:25
  • 2何博,常彬,李锋.骨肉瘤转移的分子研究进展[J].中国矫形外科杂志,2013,21(2):159-162. 被引量:6
  • 3Levy EM, Roberti MP, Mordoh J. Natural killer ceils in human canc-er:from biological functions to clinical applications [ J ]. J Biomed Biotech, 2011:1 - 11. 被引量:1
  • 4陈纲,凌斌,祝怀平,赵卫东,王群华,张红雁,吴爱东,魏海明,田志刚.自然杀伤细胞系NK-92治疗卵巢癌的体外及动物实验研究[J].中华妇产科杂志,2005,40(7):476-479. 被引量:10
  • 5Geller MA, Miller JS. Use of allogeneic NK cells for cancer immuno- therapy[ J]. Immunotherapy,2011,12 : 1445 - 1459. 被引量:1
  • 6Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK - 92 in patients with advanced renal cell cancer or mela- noma:a phase I trial [ J]. Cytotherapy,2008 ,6 :625 -632. 被引量:1
  • 7Buddingh EP, Schilham MW, Ruslan SE, et al. Chemotherapy - re- sistant osteosarcoma is highly susceptible to IL - 15 - activated allo- geneic and autologous NK cells [J]. Cancer Immunol Immunother, 2011,60:575 - 586. 被引量:1
  • 8Mori K, Radini F, Gouin F, et al. Osteosarcoma:current status of immunotherapy and future trends [ J ]. Oncology Reports, 2006,15 : 693 - 700. 被引量:1
  • 9Broady R, Manganini M, Barbui AM, et al. Stable retroviral trans- duction and expression of human CD20 gene in NK - 92 cell line : a possible innovative tool for cellular immunotherapy [ J ]. Blood ,2003, 102:2756. 被引量:1
  • 10Sanborn KB, Mace EM, Rak GD, et al. Phosphorylation of the myosin ⅡA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK - cell eytotoxicity[ J]. Blood ,2011,22 : 5862 - 5871. 被引量:1

二级参考文献105

  • 1Campanacci M. Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. New York: Springer Verlag Wien, 1999: 464-491. 被引量:1
  • 2Rosen G, Tan C, Sanmaneechai A, et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer, 1975, 35(3 suppl): 936-945. 被引量:1
  • 3Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res, 2010, 152: 239-262. 被引量:1
  • 4Kim Hi, Chalmers PN, Morris CD. Pediatric osteogenic sarcoma. Curr Opin Pediatr, 2010, 22(1): 61-66. 被引量:1
  • 5Evans AE. Mitomycin C. Cancer Chemother Rep, 1961, 14: 1-9. 被引量:1
  • 6Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer, 1979, 43(6): 2163-2177. 被引量:1
  • 7Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer, 1982, 49(6): 1221-1230. 被引量:1
  • 8Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002, 20(3): 776-790. 被引量:1
  • 9Oka K, Yakushiji T, Sato H, et al. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol, 2010, 39(2): 141-146. 被引量:1
  • 10Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncologica, 2005, 44(7): 748-755. 被引量:1

共引文献38

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部